文献速递传染病防控与疫情报告卫生政策与健康促进

利什曼病疫苗价值概况

Vaccine value profile for leishmaniasis.
PubMed 文献 · Vaccine · 2023-10-06

内脏利什曼病每年报告近2万例死亡,5岁以下儿童死亡风险最高。该疫苗价值概况由学界、公共卫生机构、政策组织和非营利组织的专家工作组基于现有公开信息编制,全面评估利什曼病疫苗的潜在公共卫生、经济和社会价值。

要点

  • 内脏利什曼病每年报告近2万例死亡,5岁以下儿童死亡风险最高。
  • 利什曼病疫苗价值概况由多领域专家工作组仅基于现有公开信息编制。

核心结论

  • 随着全球疾病负担增加以及气候变化、城市化和耐药性的威胁加剧,开发利什曼病疫苗仍有必要。
  • 早期迹象提示流行国家存在多样化的生产商组合,并有开发利什曼病疫苗的意愿。

研究设计与样本

  • 利什曼病疫苗价值概况由来自学术界、公共卫生团体、政策组织和非营利组织的主题专家工作组编制。
  • 所有贡献者在利什曼病疫苗价值概况的各方面具有广泛专业知识,共同描述了知识现状并识别了当前差距。
  • 该疫苗价值概况仅使用现有和公开可用的信息编制。

主要发现

  • 内脏利什曼病每年报告近2万例死亡,5岁以下儿童死亡风险最高。
  • 在WHO认可的被忽视热带病中,利什曼病在死亡率和发病率方面是最重要的疾病之一。
  • 正在开发理解保护相关因素和评估疫苗效力的新工具,以促进向更大规模效力试验过渡或提供替代许可途径。

局限性

  • 该疫苗价值概况仅使用现有和公开可用的信息编制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Leishmania infections are global, occurring in 98 countries and all World Health Organization (WHO) regions with 600 million to 1 billion people at risk of infection. Visceral leishmaniasis is associated with almost 20,000 reported deaths annually, with children under 5 years of age being at the greatest risk of mortality. Amongst WHO-recognised Neglected Tropical Diseases (NTDs), leishmaniasis is one of the most important in terms of mortality and morbidity. With an increasing global burden of disease and a growing threat from climate change, urbanisation and drug resistance, there remains an imperative to develop leishmaniasis vaccines. New tools to understand correlates of protection and to assess vaccine efficacy are being developed to ease the transition into larger scale efficacy trials or provide alternate routes to licensure. Early indications suggest a diverse portfolio of manufacturers exists in endemic countries with an appetite to develop leishmaniasis vaccines. This Vaccine Value Profile (VVP) provides a high-level, comprehensive assessment of the currently available data to inform the potential public health, economic, and societal value of leishmaniasis vaccines. The leishmaniasis VVP was developed by a working group of subject matter experts from academia, public health groups, policy organizations, and non-profit organizations. All contributors have extensive expertise on various elements of the leishmaniasis VVP and have collectively described the state of knowledge and identified the current gaps. The VVP was developed using only existing and publicly available information.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kaye PM, Matlashewski G, Mohan S, et al. Vaccine value profile for leishmaniasis. Vaccine. 2023. PMID: 37951693. doi:10.1016/j.vaccine.2023.01.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。